Our results showing that PD-L1 blockade is especially crucial for effective CD8+ T cell responses upon polyI:C treatment go hand-in-hand with these systemic studies suggesting that cancer immunotherapy using polyI:C would strongly benefit from anti-PD-L1 checkpoint blockade. The gene discussed is CD8A; the disease is cancer.